ArticleSkin health and disease2025
Locally advanced basal cell carcinoma treated with sonidegib:
Article in Skin health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Line-field confocal optical coherence tomography for diagnosis and treatment monitoring of subtle basal cell carcinomas in a patient with nevoid basal cell carcinoma syndrome.JAAD case reports · 2026Article
- Pathological Insights into the Limitations of Clinical and Dermoscopic Evaluations in Monitoring Sonidegib Treatment Response for Locally Advanced Basal Cell Carcinoma: A Real-World Study.Dermatology and therapy · 2026Article
- Streamlined Management of Basal Cell Carcinoma with Dermoscopy: A Retrospective Case-Control Study.Journal of clinical medicine · 2025Article
- Advanced Basal Cell Carcinoma: A Narrative Review on Current Systemic Treatments and the Neoadjuvant Approach.Journal of personalized medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hedgehog pathway inhibitors, including sonidegib and vismodegib, represent the treatment strategy for 'difficult-to-treat' basal cell carcinoma (BCC), encompassing, among others, locally advanced (laBCC) and metastatic BCC. Assessment of therapy response is challenging due to the presence of telangiectasia and scar tissue at the area of the BCC lesion. Line-field confocal optical coherence tomography (LC-OCT) is a new noninvasive imaging technique that provides high-resolution visualization of skin structures. Objectives: To investigate the value of LC-OCT for the assessment of laBCC response to sonidegib therapy. Methods: We retrospectively included patients with laBCC treated with sonidegib in the period from May 2020 to May 2023. Patients with laBCC underwent LC-OCT at baseline before starting sonidegib, and after sonidegib discontinuation when clinical complete response (CR) was reached. A subset of patients underwent LC-OCT assessment during sonidegib therapy to assess tumour persistence. Results: Twenty laBCCs in 20 patients [4 women, 16 men; mean (SD) age 76 (18) years] treated with oral sonidegib 200 mg daily were included in the study. Ten patients obtained an apparent clinical CR; LC-OCT imaging confirmed CR in 7/10 patients (70%), while in the remaining patients (3/10, 30%) LC-OCT revealed findings indicative of BCC non-CR. Ten patients were continuing sonidegib treatment: in this group LC-OCT revealed findings suggestive of BCC persistence in all 10 patients (100%). Conclusions: In this study we provide preliminary results of the beneficial use of LC-OCT in the management of patients with laBCC treated with sonidegib therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.